LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Rivera, Doris"
  2. AU="Joseph P. Habboushe"
  3. AU=Lilja Ylva
  4. AU="İnan, Dilara"
  5. AU="Roberto Castronari"
  6. AU="Malkova, Anna"
  7. AU="Wilden, L"
  8. AU="Hamel, Meriem"
  9. AU=Marim Feride
  10. AU="Zhou, Yiwang"
  11. AU="Spengler Neff, Anet" AU="Spengler Neff, Anet"
  12. AU="Stefan Barth"
  13. AU=Gong P

Suchergebnis

Treffer 1 - 5 von insgesamt 5

Suchoptionen

  1. Artikel ; Online: Tuberculosis en estudios post mortem: estudio observacional de 10 años en el Hospital General San Juan de Dios, Guatemala.

    Paz, Lizza / Rivera, Doris / Orozco, Roberto / Vasquez-Bonilla, Walter O / Argueta, Víctor

    Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia

    2018  Band 52, Heft 2, Seite(n) 76–80

    Abstract: Introduction: Tuberculosis is a very important health problem worldwide. Early detection and adequate treatment of this disease is also a problem in low income countries. Post mortem examination has enabled tuberculosis to be diagnosed, even in cases ... ...

    Titelübersetzung Post mortem examination in tuberculosis: A 10 year observational study in the San Juan de Dios General Hospital, Guatemala.
    Abstract Introduction: Tuberculosis is a very important health problem worldwide. Early detection and adequate treatment of this disease is also a problem in low income countries. Post mortem examination has enabled tuberculosis to be diagnosed, even in cases without a clinical diagnosis of the disease.
    Objective: To determine the number of tuberculosis cases diagnosed on autopsy during a period of 10 years, at the San Juan de Dios General Hospital, Guatemala (SJDGH).
    Material and methods: The final autopsy reports at the between April 2006 and March 2016 were reviewed. H&E and special stains in cases with a diagnosis of tuberculosis were revised for confirmation.
    Results: During the 10 years reviewed, 859 autopsies had been carried out, 21 of which had the diagnosis of tuberculosis; 18 were adults and 3 were children and the majority (80.95%) were cases of pulmonary tuberculosis. However, in only 5 cases had there been a clinical suspicion, but without further investigation and none had a confirmed clinical diagnosis of tuberculosis. No patients had documented HIV/AIDS.
    Conclusion: Autopsy continues to be important in the study of disease. In this retrospective study, 21 cases of tuberculosis in 21 cases were found in patients with no clinical diagnosis of the disease.
    Mesh-Begriff(e) Adolescent ; Adult ; Aged ; Autopsy ; Child ; Child, Preschool ; Female ; Guatemala/epidemiology ; Hospitals, General ; Humans ; Infant ; Male ; Middle Aged ; Retrospective Studies ; Time Factors ; Tuberculosis/epidemiology ; Tuberculosis/pathology ; Young Adult
    Sprache Spanisch
    Erscheinungsdatum 2018-11-27
    Erscheinungsland Spain
    Dokumenttyp Journal Article ; Observational Study
    ZDB-ID 2463888-2
    ISSN 1988-561X ; 1699-8855
    ISSN (online) 1988-561X
    ISSN 1699-8855
    DOI 10.1016/j.patol.2018.10.002
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Zika and Dengue Interactions in the Context of a Large Dengue Vaccine Clinical Trial in Latin America.

    Zambrano, Betzana / Noriega, Fernando / Dayan, Gustavo H / Rivera, Doris Maribel / Arredondo, José Luis / Reynales, Humberto / Luz, Kleber / Deseda, Carmen / Bonaparte, Matthew I / Langevin, Edith / Wu, Yukun / Cortés, Margarita / Savarino, Stephen / DiazGranados, Carlos A

    The American journal of tropical medicine and hygiene

    2020  Band 104, Heft 1, Seite(n) 136–144

    Abstract: A phase III dengue vaccine trial including 9- to 16-year-olds in Latin America (NCT01374516) was ongoing at the time of a Zika outbreak. We explored interactions between dengue and Zika, in the context of dengue vaccination. Symptomatic virologically ... ...

    Abstract A phase III dengue vaccine trial including 9- to 16-year-olds in Latin America (NCT01374516) was ongoing at the time of a Zika outbreak. We explored interactions between dengue and Zika, in the context of dengue vaccination. Symptomatic virologically confirmed Zika (VCZ) was evaluated using acute-phase sera from febrile participants (January 2013-March 2018). Neutralizing antibody geometric mean titers (GMTs) were evaluated pre- and post-Zika outbreak (months 25 and 72) in 2,000 randomly selected participants. Baseline dengue serostatus was determined using the plaque reduction neutralization test or inferred post hoc using nonstructural protein 1 IgG ELISA at M13 (case-cohort analysis). Vaccine efficacy against VCZ and serologically suspected Zika (SSZ) was estimated. Overall, 239/10,157 (2.4%) acute-phase samples were VCZ positive during the study. Dengue vaccine efficacy against VCZ was 27.8% (95% CI: 0.3; 47.7) among baseline dengue-seropositive participants. No vaccine effect was evident against SSZ. Zika antibody GMTs increased from pre- to post-Zika epidemic, with smaller increases observed for participants who were dengue seropositive at baseline than for those who were dengue seronegative: post-/pre-Zika GMT ratios for baseline dengue-seropositive participants were 21.5 (vaccine group) and 30.8 (placebo); and for dengue seronegatives, 88.1 and 89.5, respectively. Dengue antibody GMTs post-Zika were higher in dengue vaccine and placebo recipients with SSZ than those without SSZ in both dengue seropositives and seronegatives. Dengue vaccine did not enhance symptomatic Zika illness in dengue-seropositive individuals, rather it reduced the risk of VCZ. Zika infection boosted preexisting vaccine-induced or naturally occurring dengue-neutralizing antibodies.
    Mesh-Begriff(e) Adolescent ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; Child ; Coinfection ; Dengue/complications ; Dengue/prevention & control ; Dengue Vaccines/immunology ; Epidemics ; Female ; Humans ; Latin America/epidemiology ; Male ; Zika Virus Infection/complications
    Chemische Substanzen Antibodies, Neutralizing ; Antibodies, Viral ; Dengue Vaccines
    Sprache Englisch
    Erscheinungsdatum 2020-10-30
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2942-7
    ISSN 1476-1645 ; 0002-9637
    ISSN (online) 1476-1645
    ISSN 0002-9637
    DOI 10.4269/ajtmh.20-0635
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ud II Zs.61: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.

    Coronel, Diana / García-Rivera, Enid J / Rivera, Doris Maribel / Arredondo-García, José Luis / Dietze, Reynaldo / Perroud, Ana Paula / Cortés, Margarita / Bonaparte, Matthew / Wang, Hao / Pagnon, Anke / Jantet-Blaudez, Frédérique / Peñalosa, Luis Andrey Rojas / Dayan, Gustavo / Zambrano, Betzana / DiazGranados, Carlos A / Noriega, Fernando

    The Pediatric infectious disease journal

    2020  Band 39, Heft 10, Seite(n) 961–968

    Abstract: Background: We previously described an increased immune response 28 days after a booster dose of the live, attenuated, tetravalent dengue vaccine (CYD-TDV) in healthy adolescents and adults in Latin America (CYD64, NCT02623725). This follow-up study ... ...

    Abstract Background: We previously described an increased immune response 28 days after a booster dose of the live, attenuated, tetravalent dengue vaccine (CYD-TDV) in healthy adolescents and adults in Latin America (CYD64, NCT02623725). This follow-up study evaluated immune response persistence and safety of a CYD-TDV booster dose up to Month (M) 24 post-booster.
    Methods: This study included 250 participants who previously received 3 primary doses of CYD-TDV in the CYD13 (NCT00993447) and CYD30 (NCT01187433) studies, and who were randomized 4-5 years later to receive a CYD-TDV booster or placebo (3:1). Dengue neutralizing antibodies against the parental dengue virus strains were assessed using the plaque reduction neutralization test (PRNT50) at M6, M12, and M24 post-booster. Post-booster memory B-cell responses were assessed in a subset of participants using the FluoroSpot assay up to M12 post-booster.
    Results: In the CYD-TDV group (n = 187), dengue neutralizing antibody geometric mean titers (GMTs) declined from the peak at day 28 through to M24 for all serotypes. GMTs at M24 were similar to those at pre-booster among baseline dengue seropositives. A similar trend was observed for baseline dengue seronegatives, albeit at a lower magnitude. Previous vaccination-induced detectable B-cell memory responses in seropositives and seronegatives that decreased to pre-booster levels at M12 post-booster. The CYD-TDV booster dose was well-tolerated.
    Conclusions: In baseline dengue seropositives, following a CYD-TDV booster dose administered 4-5 years after primary immunization, dengue neutralizing antibody GMTs and B-cell memory responses peaked in the short-term before gradually decreasing over time. A CYD-TDV booster dose could improve protection against dengue during outbreak periods.
    Mesh-Begriff(e) Adolescent ; Adult ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; Child ; Dengue/prevention & control ; Dengue Vaccines/administration & dosage ; Dengue Vaccines/immunology ; Dengue Virus/immunology ; Female ; Follow-Up Studies ; Humans ; Immunization Schedule ; Immunization, Secondary/methods ; Immunologic Memory ; Latin America ; Male ; Neutralization Tests ; Vaccines, Combined/administration & dosage ; Vaccines, Combined/immunology
    Chemische Substanzen Antibodies, Neutralizing ; Antibodies, Viral ; Dengue Vaccines ; Vaccines, Combined
    Sprache Englisch
    Erscheinungsdatum 2020-09-15
    Erscheinungsland United States
    Dokumenttyp Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 392481-6
    ISSN 1532-0987 ; 0891-3668
    ISSN (online) 1532-0987
    ISSN 0891-3668
    DOI 10.1097/INF.0000000000002830
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1852: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines

    de Bruyn, Guy / Wang, Joyce / Purvis, Annie / Sanchez Ruiz, Martin / Adhikarla, Haritha / Alvi, Saad / Bonaparte, Matthew I / Brune, Daniel / Bueso, Agustin / Canter, Richard M / Angeles Ceregido, Maria / Diemert, David / Finn, Adam / Forrat, Remi / Fu, Bo / Gallais, Julie / Griffin, Paul / Grillet, Marie-Helene / Haney, Owen /
    Henderson, Jeffrey A / Koutsoukos, Marguerite / Launay, Odile / Martinon Torres, Federico / Masotti, Roger / Michael, Nelson L / Park, Juliana / Rivera, Doris M / Romanyak, Natalya / Rook, Chris / Schuerman, Lode / Sher, Lawrence D / Tavares-Da-Silva Sachin Deshmukh, Fernanda / Whittington, Ashley / Chicz, Roman M / Gurunathan, Sanjay / Savarino, Stephen / Sridhar, Saranya / VAT00002 booster cohorts study team

    medRxiv

    Abstract: Background Booster vaccines providing protection against emergent SARS-CoV-2 variants are needed. In an international phase 3 study, we evaluated booster vaccines containing prototype (D614) and/or Beta (B.1.351) variant recombinant spike proteins and ... ...

    Abstract Background Booster vaccines providing protection against emergent SARS-CoV-2 variants are needed. In an international phase 3 study, we evaluated booster vaccines containing prototype (D614) and/or Beta (B.1.351) variant recombinant spike proteins and AS03 adjuvant (CoV2 preS dTM-AS03). Methods Adults, primed 4-10 months earlier with mRNA (BNT162b2, mRNA-1273]), adenovirus-vectored (Ad26.CoV2.S, ChAdOx1nCoV-19) or adjuvanted protein (CoV2 preS dTM-AS03 [D614]) vaccines and stratified by age (18-55 and ≥56 years), were boosted with monovalent (MV) D614 (5≥g, n=1285), MV (B.1351) (5μg, n=707) or bivalent (BiV) (2.5≥g D614 plus 2.5≥g B.1.351, n=625) CoV2 preS dTM-AS03. SARS-CoV-2-naïve adults (controls, n=479) received a primary series (two injections, 21 days apart) of CoV2 preS dTM-AS03 containing 10μg D614. Antibodies to D614G, B.1.351 and Omicron BA.2 and BA.1 variants were evaluated using validated pseudovirus (lentivirus) neutralization (PsVN) assay. D614G or B.1.351 PsVN titers 14 days (D15) post-booster were compared with pre-booster (D1) titers in BNT162b2-primed participants (18-55 years old) and controls (D36), for each booster formulation (co-primary objectives). Safety was evaluated throughout the trial. Results of a planned interim analysis are presented. Results Among BNT162b2-primed adults (18-55 years old), PsVN titers against D614G or B.1.351 were significantly higher post-booster than anti-D614G titers post-primary vaccination in controls, for all booster formulations, with an anti-D614G GMT ratio (98.3% CI) of 2.16 (1.69; 2.75) for MV(D614), an anti-B.1.351 ratio of 1.96 (1.54; 2.50) for MV (B.1.351) and anti-D614G and anti-B.1.351 ratios of 2.34 (1.84; 2.96) and 1.39 (1.09; 1.77), respectively, for BiV. All booster formulations elicited cross-neutralizing antibodies against Omicron BA.2 across vaccine priming subgroups and against Omicron BA.1 (evaluated in BNT162b2-primed participants). Similar patterns in antibody responses were observed for participants aged ≥56 years. No safety concerns were identified. Conclusion CoV2 preS dTM-AS03 boosters demonstrated acceptable safety and elicited robust neutralizing antibodies against multiple variants, regardless of priming vaccine. ClinicalTrials.gov: NCT04762680
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2022-12-03
    Verlag Cold Spring Harbor Laboratory Press
    Dokumenttyp Artikel ; Online
    DOI 10.1101/2022.12.02.22282931
    Datenquelle COVID19

    Volltext online

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  5. Artikel ; Online: Efficacy of a tetravalent dengue vaccine in children in Latin America.

    Villar, Luis / Dayan, Gustavo Horacio / Arredondo-García, José Luis / Rivera, Doris Maribel / Cunha, Rivaldo / Deseda, Carmen / Reynales, Humberto / Costa, Maria Selma / Morales-Ramírez, Javier Osvaldo / Carrasquilla, Gabriel / Rey, Luis Carlos / Dietze, Reynaldo / Luz, Kleber / Rivas, Enrique / Miranda Montoya, Maria Consuelo / Cortés Supelano, Margarita / Zambrano, Betzana / Langevin, Edith / Boaz, Mark /
    Tornieporth, Nadia / Saville, Melanie / Noriega, Fernando

    The New England journal of medicine

    2015  Band 372, Heft 2, Seite(n) 113–123

    Abstract: Background: In light of the increasing rate of dengue infections throughout the world despite vector-control measures, several dengue vaccine candidates are in development.: Methods: In a phase 3 efficacy trial of a tetravalent dengue vaccine in five ...

    Abstract Background: In light of the increasing rate of dengue infections throughout the world despite vector-control measures, several dengue vaccine candidates are in development.
    Methods: In a phase 3 efficacy trial of a tetravalent dengue vaccine in five Latin American countries where dengue is endemic, we randomly assigned healthy children between the ages of 9 and 16 years in a 2:1 ratio to receive three injections of recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) or placebo at months 0, 6, and 12 under blinded conditions. The children were then followed for 25 months. The primary outcome was vaccine efficacy against symptomatic, virologically confirmed dengue (VCD), regardless of disease severity or serotype, occurring more than 28 days after the third injection.
    Results: A total of 20,869 healthy children received either vaccine or placebo. At baseline, 79.4% of an immunogenicity subgroup of 1944 children had seropositive status for one or more dengue serotypes. In the per-protocol population, there were 176 VCD cases (with 11,793 person-years at risk) in the vaccine group and 221 VCD cases (with 5809 person-years at risk) in the control group, for a vaccine efficacy of 60.8% (95% confidence interval [CI], 52.0 to 68.0). In the intention-to-treat population (those who received at least one injection), vaccine efficacy was 64.7% (95% CI, 58.7 to 69.8). Serotype-specific vaccine efficacy was 50.3% for serotype 1, 42.3% for serotype 2, 74.0% for serotype 3, and 77.7% for serotype 4. Among the severe VCD cases, 1 of 12 was in the vaccine group, for an intention-to-treat vaccine efficacy of 95.5%. Vaccine efficacy against hospitalization for dengue was 80.3%. The safety profile for the CYD-TDV vaccine was similar to that for placebo, with no marked difference in rates of adverse events.
    Conclusions: The CYD-TDV dengue vaccine was efficacious against VCD and severe VCD and led to fewer hospitalizations for VCD in five Latin American countries where dengue is endemic. (Funded by Sanofi Pasteur; ClinicalTrials.gov number, NCT01374516.).
    Mesh-Begriff(e) Adolescent ; Antibodies, Viral/blood ; Child ; Dengue/immunology ; Dengue/prevention & control ; Dengue/virology ; Dengue Vaccines/immunology ; Dengue Virus/genetics ; Dengue Virus/immunology ; Dengue Virus/isolation & purification ; Endemic Diseases/prevention & control ; Female ; Hospitalization ; Humans ; Intention to Treat Analysis ; Latin America ; Male ; Serogroup ; Severity of Illness Index ; Single-Blind Method ; Treatment Outcome ; Vaccines, Attenuated/immunology
    Chemische Substanzen Antibodies, Viral ; Dengue Vaccines ; Vaccines, Attenuated
    Sprache Englisch
    Erscheinungsdatum 2015-01-08
    Erscheinungsland United States
    Dokumenttyp Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMoa1411037
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ua VI Zs.34: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang